Back to Search
Start Over
Totality of evidence refutes neoplasm risk with fezolinetant.
- Source :
-
Lancet (London, England) [Lancet] 2024 May 18; Vol. 403 (10440), pp. 1987-1988. - Publication Year :
- 2024
Details
- Language :
- English
- ISSN :
- 1474-547X
- Volume :
- 403
- Issue :
- 10440
- Database :
- MEDLINE
- Journal :
- Lancet (London, England)
- Publication Type :
- Editorial & Opinion
- Accession number :
- 38762322
- Full Text :
- https://doi.org/10.1016/S0140-6736(24)00709-8